ATE521629T1 - Matrixmetalloproteinase-11-impfstoff - Google Patents
Matrixmetalloproteinase-11-impfstoffInfo
- Publication number
- ATE521629T1 ATE521629T1 AT06792355T AT06792355T ATE521629T1 AT E521629 T1 ATE521629 T1 AT E521629T1 AT 06792355 T AT06792355 T AT 06792355T AT 06792355 T AT06792355 T AT 06792355T AT E521629 T1 ATE521629 T1 AT E521629T1
- Authority
- AT
- Austria
- Prior art keywords
- mmp
- compositions
- terminus
- linked
- immunoenhancing element
- Prior art date
Links
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 title abstract 10
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 102000011723 Matrix Metalloproteinase 11 Human genes 0.000 title 1
- 102100028847 Stromelysin-3 Human genes 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000002766 immunoenhancing effect Effects 0.000 abstract 3
- 102000017303 Stromelysin-3 Human genes 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72449805P | 2005-10-07 | 2005-10-07 | |
| PCT/EP2006/009536 WO2007042169A2 (en) | 2005-10-07 | 2006-10-03 | Matrix metalloproteinase 11 vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521629T1 true ATE521629T1 (de) | 2011-09-15 |
Family
ID=37451271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06792355T ATE521629T1 (de) | 2005-10-07 | 2006-10-03 | Matrixmetalloproteinase-11-impfstoff |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8106176B2 (enExample) |
| EP (1) | EP1934246B8 (enExample) |
| JP (1) | JP5361386B2 (enExample) |
| CN (1) | CN101365715B (enExample) |
| AT (1) | ATE521629T1 (enExample) |
| AU (1) | AU2006301582B2 (enExample) |
| CA (1) | CA2623531C (enExample) |
| ES (1) | ES2370040T3 (enExample) |
| WO (1) | WO2007042169A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| PT2340031T (pt) | 2008-08-14 | 2019-07-25 | Acceleron Pharma Inc | Armadilhas de gdf para uso no tratamento de anemia |
| EP2342334A4 (en) * | 2008-09-29 | 2012-03-14 | Univ Pennsylvania | VACCINES DIRECTED TO TUMOR VESSEL MARKERS |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| EP2770980A4 (en) | 2011-10-25 | 2015-11-04 | Univ British Columbia | LOW SIZE LIPID NANOPARTICLES AND METHODS THEREOF |
| EP2971013B1 (en) | 2013-03-15 | 2020-08-19 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| PH12021550850A1 (en) | 2015-03-27 | 2022-10-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| WO2018156106A1 (en) * | 2017-02-22 | 2018-08-30 | Ding Enyu | An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes |
| CN115003820A (zh) * | 2019-10-08 | 2022-09-02 | 爱科霍拉有限公司 | 用于眼部治疗的组合物和方法 |
| WO2022220603A1 (ko) | 2021-04-16 | 2022-10-20 | 고려대학교 산학협력단 | 코로나-19 바이러스 표적 인간 항체 |
| GB202117583D0 (en) * | 2021-12-06 | 2022-01-19 | Cambridge Entpr Ltd | Protein expression |
| CN116590263A (zh) * | 2023-07-02 | 2023-08-15 | 广州庆毅生物医药科技有限公司 | 一种重组蛋白、单克隆抗体及其检测试剂盒和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| GB9112553D0 (en) | 1991-06-11 | 1991-07-31 | Wellcome Found | Fusion proteins |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5945399A (en) * | 1996-05-23 | 1999-08-31 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| CA2369058A1 (en) | 1999-04-26 | 2000-11-02 | K.U. Leuven Research & Development | Synthetic gene for expressing active retroviral protein in eukaryotes |
| JP2003511061A (ja) * | 1999-10-08 | 2003-03-25 | アクティブ バイオテック エイビー | 変更された化学結合体化特性を有するａｂ５毒素ｂサブユニット変異体 |
| GB9930768D0 (en) * | 1999-12-29 | 2000-02-16 | Pfizer Ltd | Composition |
| CA2422882A1 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| US20040110152A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of matrix metalloproteinase 11 expression |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| MXPA06003977A (es) * | 2003-10-10 | 2006-06-27 | Powderject Vaccines Inc | Metodo. |
| BRPI0507579A (pt) | 2004-02-11 | 2007-07-03 | Angeletti P Ist Richerche Bio | molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea |
-
2006
- 2006-10-03 US US12/083,031 patent/US8106176B2/en active Active
- 2006-10-03 CN CN2006800370642A patent/CN101365715B/zh not_active Expired - Fee Related
- 2006-10-03 WO PCT/EP2006/009536 patent/WO2007042169A2/en not_active Ceased
- 2006-10-03 AT AT06792355T patent/ATE521629T1/de not_active IP Right Cessation
- 2006-10-03 EP EP06792355A patent/EP1934246B8/en active Active
- 2006-10-03 AU AU2006301582A patent/AU2006301582B2/en not_active Ceased
- 2006-10-03 JP JP2008533917A patent/JP5361386B2/ja not_active Expired - Fee Related
- 2006-10-03 ES ES06792355T patent/ES2370040T3/es active Active
- 2006-10-03 CA CA2623531A patent/CA2623531C/en not_active Expired - Fee Related
-
2011
- 2011-12-21 US US13/332,580 patent/US8492522B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2623531C (en) | 2013-12-10 |
| CA2623531A1 (en) | 2007-04-19 |
| JP5361386B2 (ja) | 2013-12-04 |
| US20090155298A1 (en) | 2009-06-18 |
| WO2007042169A2 (en) | 2007-04-19 |
| AU2006301582A1 (en) | 2007-04-19 |
| CN101365715A (zh) | 2009-02-11 |
| EP1934246A2 (en) | 2008-06-25 |
| AU2006301582B2 (en) | 2011-10-13 |
| EP1934246B8 (en) | 2012-02-08 |
| US8106176B2 (en) | 2012-01-31 |
| EP1934246B1 (en) | 2011-08-24 |
| WO2007042169A3 (en) | 2007-05-31 |
| ES2370040T3 (es) | 2011-12-12 |
| JP2009509553A (ja) | 2009-03-12 |
| US20120177679A1 (en) | 2012-07-12 |
| US8492522B2 (en) | 2013-07-23 |
| CN101365715B (zh) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521629T1 (de) | Matrixmetalloproteinase-11-impfstoff | |
| PH12023550266A1 (en) | Anti-ceacam5 antibodies and conjugates and uses thereof | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| DK1549353T3 (da) | Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer | |
| BRPI0509201A (pt) | agentes de acoplamento de receptor e usos terapêuticos destes | |
| TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
| MY149604A (en) | C.perfringens alpha toxoid vaccine | |
| HUP0203968A2 (hu) | Készítmények és eljárások prosztatarák terápiájára és diagnózisára | |
| DK1922335T3 (da) | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler | |
| WO2002089747A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
| WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2001073032A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| EA200970607A1 (ru) | Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| AR031250A1 (es) | Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon | |
| ATE404669T1 (de) | In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide | |
| MX2021015533A (es) | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. | |
| ES2187568T3 (es) | Vacuna viva para el tratamiento de enfermedades tumorales. | |
| MX2009003679A (es) | Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. | |
| MXPA05010575A (es) | Peptacuerpo para el tratamiento del cancer. | |
| WO2008036973A3 (en) | Modulating regulatory t cell activity via interleukin 35 | |
| ES2061521T3 (es) | Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |